Skip to search formSkip to main contentSkip to account menu

bortezomib

Known as: Bortezomib [Chemical/Ingredient], N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide, [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid 
A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that… 
National Institutes of Health

Related topics

Related topics

31 relations
Angiogenesis InhibitionBortezomib-Dexamethasone RegimenBortezomib/Cyclophosphamide/Dexamethasone RegimenBortezomib/Dexamethasone/Lenalidomide Regimen

Broader (1)

Antineoplastic Agents

Narrower (4)

LDP-341MLN341PS 341Velcade

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
BACKGROUND Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and… 
Highly Cited
2013
Highly Cited
2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Highly Cited
2012
Highly Cited
2012
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
Histone deacetylase (HDAC) enzymatic activity has been linked to the transcription of DNA in cancers including multiple myeloma… 
Highly Cited
2010
Highly Cited
2010
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.
In a recent phase 3 trial, bortezomib-melphalan-prednisone-thalidomide followed by maintenance treatment with bortezomib… 
Highly Cited
2008
Highly Cited
2008
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Autoantibody-mediated diseases like myasthenia gravis, autoimmune hemolytic anemia and systemic lupus erythematosus represent a… 
Review
2008
Review
2008
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature.
Bortezomib has demonstrated significant activity in clinical trials, mainly against recurrent or newly diagnosed multiple myeloma… 
Highly Cited
2006
Highly Cited
2006
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PURPOSE To determine the frequency, characteristics, and reversibility of peripheral neuropathy from bortezomib treatment of… 
Review
2005
Review
2005
Clinical Trials and Observations
Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the… 
Review
2004
Review
2004
Development of the Proteasome Inhibitor Velcade™ (Bortezomib)
The dipeptide boronic acid analogue VELCADE™ (Bortezomib; formerly known as PS-341, LDP-341 and MLM341) is a potent and selective… 
Review
2004
Review
2004
The development of proteasome inhibitors as anticancer drugs.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)